After a failed therapy with FOLFOX and pembrolizumab, the patient was started on a regimen of vemurafenib, irinotecan, and cetuximab (VIC) based on the SWOG 1406 trial which had shown improved progression-free survival and response rate for the treatment of BRAF<sup>V600E</sup>-mutant metastatic CRC. The gene discussed is BRAF; the disease is colorectal carcinoma.